Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sam Schulman

Showing results (51-60 of 308) with videos related to

Pageof 31
Sort By:
Seminars in Thrombosis and Hemostasis|November 11, 2014
When the rubber meets the road: adherence and persistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagulants in the real world-a problem or a myth ?Deepa Suryanarayan, Sam Schulman
Drug Safety|May 19, 2011
A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgerySam Schulman, Ammar Majeed
Seminars in Thrombosis and Hemostasis|February 14, 2009
Determinants of bleeding risk in patients on antithrombotic and antifibrinolytic drugsKarina Meijer, Sam Schulman
BMJ (Clinical Research Ed.)|September 11, 2013
Secondary prevention of venous thromboembolismSam Schulman, James Douketis
Best Practice & Research. Clinical Haematology|August 20, 2013
Bleeding and antidotes in new oral anticoagulantsAmmar Majeed, Sam Schulman
Thrombosis and Haemostasis|April 8, 2021
Anticoagulant Treatment of COVID-19 as Early as Possible-Sulodexide and PerspectivesSam Schulman, Job Harenberg
Seminars in Thrombosis and Hemostasis|September 24, 2020
New-Onset Atrial Fibrillation in Sepsis: A Narrative ReviewJesus Aibar, Sam Schulman
Seminars in Thrombosis and Hemostasis|May 10, 2021
Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-AnalysisJesus Aibar, Sam Schulman
Journal of the American College of Cardiology|July 18, 2018
Are NSAIDs Double Trouble?Sam Schulman, James Aisenberg
Anesthesiology|August 16, 2019
Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X InhibitorsOliver Grottke, Sam Schulman
Pageof 31

Showing results (51-60 of 308) with videos related to

Sort By:
Pageof 31
Seminars in Thrombosis and Hemostasis|November 11, 2014
When the rubber meets the road: adherence and persistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagulants in the real world-a problem or a myth ?Deepa Suryanarayan, Sam Schulman
Drug Safety|May 19, 2011
A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgerySam Schulman, Ammar Majeed
Seminars in Thrombosis and Hemostasis|February 14, 2009
Determinants of bleeding risk in patients on antithrombotic and antifibrinolytic drugsKarina Meijer, Sam Schulman
BMJ (Clinical Research Ed.)|September 11, 2013
Secondary prevention of venous thromboembolismSam Schulman, James Douketis
Best Practice & Research. Clinical Haematology|August 20, 2013
Bleeding and antidotes in new oral anticoagulantsAmmar Majeed, Sam Schulman
Thrombosis and Haemostasis|April 8, 2021
Anticoagulant Treatment of COVID-19 as Early as Possible-Sulodexide and PerspectivesSam Schulman, Job Harenberg
Seminars in Thrombosis and Hemostasis|September 24, 2020
New-Onset Atrial Fibrillation in Sepsis: A Narrative ReviewJesus Aibar, Sam Schulman
Seminars in Thrombosis and Hemostasis|May 10, 2021
Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-AnalysisJesus Aibar, Sam Schulman
Journal of the American College of Cardiology|July 18, 2018
Are NSAIDs Double Trouble?Sam Schulman, James Aisenberg
Anesthesiology|August 16, 2019
Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X InhibitorsOliver Grottke, Sam Schulman
Pageof 31